123 related articles for article (PubMed ID: 35533245)
1. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Saini NY; Swoboda DM; Greenbaum U; Ma J; Patel RD; Devashish K; Das K; Tanner MR; Strati P; Nair R; Fayad L; Ahmed S; Lee HJ; Iyer SP; Steiner R; Jain N; Nastoupil L; Loghavi S; Tang G; Bassett RL; Jain P; Wang M; Westin JR; Green MR; Sallman DA; Padron E; Davila ML; Locke FL; Champlin RE; Garcia-Manero G; Shpall EJ; Kebriaei P; Flowers CR; Jain MD; Wang F; Futreal AP; Gillis N; Neelapu SS; Takahashi K
Blood Cancer Discov; 2022 Sep; 3(5):385-393. PubMed ID: 35533245
[TBL] [Abstract][Full Text] [Related]
2. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH; Nath K; Devlin SM; Sauter CS; Palomba ML; Shah G; Dahi P; Lin RJ; Scordo M; Perales MA; Shouval R; Tomas AA; Cathcart E; Mead E; Santomasso B; Holodny A; Brentjens RJ; Riviere I; Sadelain M
Nat Med; 2023 Jul; 29(7):1710-1717. PubMed ID: 37400640
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
[TBL] [Abstract][Full Text] [Related]
4. Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy.
Jalota A; Hershberger CE; Patel MS; Mian A; Faruqi A; Khademi G; Rotroff DM; Hill BT; Gupta N
Blood Adv; 2023 Sep; 7(17):4690-4700. PubMed ID: 36399526
[TBL] [Abstract][Full Text] [Related]
5. The crossroads of cancer therapies and clonal hematopoiesis.
Singh A; Balasubramanian S
Semin Hematol; 2024 Feb; 61(1):16-21. PubMed ID: 38403501
[TBL] [Abstract][Full Text] [Related]
6. Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma.
Yan C; Richard MA; Gibson CJ; He J; Bosworth A; Crossman DK; Singh P; Hageman L; Kalra R; Armenian SH; Vose J; Weisdorf DJ; Ebert BL; Yasui Y; Forman SJ; Bhatia R; Bhatia S
J Clin Oncol; 2024 Apr; ():JCO2302547. PubMed ID: 38635938
[TBL] [Abstract][Full Text] [Related]
7. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Saygin C; Zhang P; Stauber J; Aldoss I; Sperling AS; Weeks LD; Luskin MR; Knepper TC; Wanjari P; Wang P; Lager AM; Fitzpatrick C; Segal JP; Gharghabi M; Gurbuxani S; Venkataraman G; Cheng JX; Eisfelder BJ; Bohorquez O; Patel AA; Umesh Nagalakshmi S; Jayaram S; Odenike OM; Larson RA; Godley LA; Arber DA; Gibson CJ; Munshi NC; Marcucci G; Ebert BL; Greally JM; Steidl U; Lapalombella R; Shah BD; Stock W
Blood Cancer Discov; 2024 May; 5(3):164-179. PubMed ID: 38150184
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends CM; Kopp K; Hablesreiter R; Estrada N; Christen F; Moll UM; Zeillinger R; Schmitt WD; Sehouli J; Kulbe H; Fleischmann M; Ray-Coquard I; Zeimet A; Raspagliesi F; Zamagni C; Vergote I; Lorusso D; Concin N; Bullinger L; Braicu EI; Damm F
Leukemia; 2024 Apr; ():. PubMed ID: 38637689
[TBL] [Abstract][Full Text] [Related]
9. Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial.
Woo J; Zhai T; Yang F; Xu H; Healey ML; Yates DP; Beste MT; Steensma DP
Cancer Prev Res (Phila); 2024 May; ():. PubMed ID: 38701435
[TBL] [Abstract][Full Text] [Related]
10. Multiomic Profiling of Human Clonal Hematopoiesis Reveals Genotype and Cell-Specific Inflammatory Pathway Activation.
Heimlich JB; Bhat P; Parker A; Jenkins MT; Vlasschaert C; Ulloa J; Van Amburg J; Potts CR; Olson S; Silver AJ; Ahmad A; Sharber B; Brown D; Hu N; van Galen P; Savona MR; Bick AG; Ferrell PB
Blood Adv; 2024 Mar; ():. PubMed ID: 38507736
[TBL] [Abstract][Full Text] [Related]
11. Clonal Hematopoiesis and Inflammation in the VasculaturE (CHIVE): a prospective, longitudinal cohort and biorepository.
Shannon ML; Heimlich JB; Olson S; Debevec A; Copeland Z; Kishtagari A; Vlasschaert C; Snider CA; Silver AJ; Brown D; Spaulding TP; Bhatta MR; Pugh K; Stockton SS; Ulloa J; Xu Y; Baljevic M; Moslehi J; Jahangir E; Ferrell PB; Slosky DA; Bick AG; Savona MR
Blood Adv; 2024 Apr; ():. PubMed ID: 38608257
[TBL] [Abstract][Full Text] [Related]
12. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
[TBL] [Abstract][Full Text] [Related]
13. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.
Fahrmann JF; Saini NY; Chia-Chi C; Irajizad E; Strati P; Nair R; Fayad LE; Ahmed S; Lee HJ; Iyer S; Steiner R; Vykoukal J; Wu R; Dennison JB; Nastoupil L; Jain P; Wang M; Green M; Westin J; Blumenberg V; Davila M; Champlin R; Shpall EJ; Kebriaei P; Flowers CR; Jain M; Jenq R; Stein-Thoeringer CK; Subklewe M; Neelapu SS; Hanash S
Cell Rep Med; 2022 Nov; 3(11):100720. PubMed ID: 36384092
[TBL] [Abstract][Full Text] [Related]
14. CAR T-cell Therapy Meets Clonal Hematopoiesis.
Uslu U; June CH
Blood Cancer Discov; 2022 Sep; 3(5):382-384. PubMed ID: 35896010
[TBL] [Abstract][Full Text] [Related]
15. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
Ahmed N; Wesson W; Mushtaq MU; Porter DL; Nasta SD; Brower J; Bachanova V; Hu M; Nastoupil LJ; Oluwole OO; Patel VG; Oliai C; Riedell PA; Bishop MR; Shah GL; Perales MA; Schachter L; Maziarz RT; McGuirk JP
Transplant Cell Ther; 2023 Jul; 29(7):449.e1-449.e7. PubMed ID: 37120134
[TBL] [Abstract][Full Text] [Related]
16. Expression of Concern: Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Blood Cancer Discov; 2023 May; 4(3):246. PubMed ID: 37042811
[No Abstract] [Full Text] [Related]
17. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
18. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
[TBL] [Abstract][Full Text] [Related]
20. Clonal Hematopoiesis and Its Impact on Human Health.
Ahmad H; Jahn N; Jaiswal S
Annu Rev Med; 2023 Jan; 74():249-260. PubMed ID: 36450282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
